Gene marking can be used to investigate if progenitor cells harvested from patients are contaminated with tumorigenic cells. It can also provide information about the contribution of hematopoietic stem cells to long-term engraftment and about long-term transgene expression from integrated retroviral vectors. In order to study autologous-infused cell contribution to relapse as well as the long-term persistence of the transgene in hematopoietic cells following autologous bone marrow (BM) transplantation for multiple myeloma, we genetically marked autologous CD34 þ enriched BM or peripheral blood cell grafts of eight myeloma patients using retroviral vectors. Six patients were subsequently transplanted with the marked graft and followed with regular time points of analysis. Briefly, mononuclear cells were harvested by leukapheresis during 2-4 consecutive days following priming with granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF. The CD34 þ cells separated on Cellpro ceprate avidinbiotin columns were exposed to the G1Na vector coding for neomycin resistance gene at a ratio of five vector particles per cell at three consecutive time points achieving an average transduction efficacy of 2% (0.43-5.1%). The patients were transplanted with a mixture of transduced cells and un-manipulated graft. Vector integration and transgene expression were analyzed by colony assays and polymerase chain reaction. The transgene could be detected for up to 5 years post-transplant in normal BM cells, even in remission following relapse and no side effects related to retroviral gene transfer were observed. There were no marked myeloma cells observed in the patients either in remission or in relapsing disease, which indicates that contribution of infused cells to relapse is unlikely.
Introduction
Multiple myeloma is a plasma-cell neoplasm with a median length of survival after diagnosis of approximately 3 years. Although the disease remains incurable, current main alternatives are drug treatment modalities 1 and autologous stem cell transplantation (ASCT). 2, 3 Most often a combination of vincristine, doxorubicin and dexamethasone (VAD) or VAD-like regimens are used as induction therapy before a stem cell harvest, which is followed by a single or tandem ASCT. Although the ASCT may improve survival, relapse and progression remain the major causes of treatment failure. As the hematopoietic stem cell (HSC) harvest for autologous transplants is performed in complete or partial remission, at a time when, by definition, the number of malignant cells is low or under detection level, the effectiveness of tumor cell eradication cannot be fully estimated. [4] [5] [6] It remains an uncertainty whether malignant cells potentially contaminating the HSC harvest and re-infused with the ASCT may contribute to subsequent relapse. Thus, the role of ASCT in multiple myeloma needs to be defined in order to increase treatment efficacy and improve the outcome of this disease.
One approach to clarify the role of ASCT is to genetically mark the graft before transplantation to investigate the presence of the marker gene in normal hematopoietic cells and in malignant cells at the time of a subsequent relapse. This strategy has previously been used to track the in vivo behavior of a variety of cell types. A majority of gene marking studies performed has used murine retroviral vectors, as marked cells and their progeny can be traced with viral vectors integrating in the genomic DNA. Several marker genes have been used for gene marking studies both in vitro and in vivo. These include the Escherichia coli b-galactosidase gene (lacZ), 7 green fluorescent protein, [8] [9] [10] murine CD24, 11 the lowaffinity nerve growth factor receptor 12, 13 and the ouabain resistance gene (Oua r ).
14 In one study, the marker neomycin phosphotransferase gene (neo r ) 15 was detectable for up to 5 years in the mature progeny of marrow precursor cells in AML patients, signifying successful stem cell transduction and engraftment of marked stem cells. 16 Also in a similar study of six myeloma and six breast cancer patients, the neo r was detected transiently in normal but not tumor cells in vivo. 17 The results could be due to a low transduction efficiency rather than unfeasibility to transduce tumor cells, as we have shown that myeloma cells can be successfully transduced with retroviral vectors. 18 Here, we used retroviral vector-mediated gene transfer (RMGT) to mark CD34 þ sorted bone marrow (BM) and peripheral blood (PB) stem cells used for ASCT in patients with multiple myeloma. We addressed whether the myeloma cells of relapsing patients contained the marker gene and if the transgene was detectable in hematopoietic cells of patients both for short and long term after transplantation.
Results

Patients
Altogether eight patients were admitted to the study, of which six received the gene-modified graft and were analyzed for transgene presence in the PB and BM cells. Patients were treated with VAD or VAD-like regimens before cell harvest. Mobilization was performed using cyclophosphamide (2 g) and G-CSF or granulocytemacrophage colony-stimulating factor (GM-CSF). The response status at time of harvest is seen in Table 1 . Conditioning was made using melphalan 200 mg/m 2 . Two patients died before the date set for transplantation (preliminary data have been reported previously 19 ). Two of the six transplanted patients died within a year after transplantation. One of them had a fatal pneumonia and died 6 months after transplantation. The other had a fast and early disease recurrence 10 months after transplantation and died subsequently. The patient characteristics during the study are summarized in Table 1 .
Transduction of CD34
þ cells The median total cell count was 3.53 Â 10 10 before and 2.46 Â 10 8 after CD34 þ cell separation. The cells were exposed to the G1Na vector at a ratio of five vector particles per cell, in vector containing supernatant for 12 h in the presence of stem cell factor, interleukin-3, interleukin-6, basic fibroblast growth factor and protamine sulfate. The transduction was repeated twice for 6 h. The cells were then frozen for re-infusion. The average transduction efficacy of CD34 þ enriched cells was 2% (0.43-5.1%). The transduction and selection results are summarized in more detail in Table 2 .
Long-term analysis of transgene
The PB and BM of the patients were analyzed regularly by colony assays and polymerase chain reaction (PCR). Expression (1-5%) of the transgene was observed in colonies for up to 6 months. After 6 months, colony assays became negative but the transgene was still detectable by the nested PCR technique ( Table 3 ). The existence of the transgene over time (5 years) confirmed that HSCs were transduced and engrafted ( Figure 1 ). The number of cells having the transgene was analyzed by quantitative PCR (Q-PCR) using total genomic DNA from BM of patients 1, 5 and 7. Results of Q-PCR analysis revealed the presence of the transgene in samples from patient 1, 5 and 7, at days 705, 1106 and 1141 after transplant, respectively. Simultaneously, the expression of the transgene was also checked by reverse transcriptase PCR (RT-PCR) but none was detected. Q-PCR results showed that the transgene was present in less than 1 in 10 5 cells, which is below detection threshold for RT-PCR and therefore explains why RT-PCR results of the same samples were negative. Tumor cells in the BM biopsy materials from three patients in relapse were not marked with the transgene (Figure 2a) . Noteworthy, the transgene Abbreviations: A, doxorubicin; BM, bone marrow; D, dexamethasone; F, female; M, male; PR, partial remission; PBSC, peripheral blood stem cell; V, vincristine; B, BNCU (Carmustine); C, cyclophosphamide; M, melphalan; P, prednisone.
Patient no. 1 received BM cells and all others received PBSCs.
Long-term follow-up of gene-marked CD34 þ cells E Alici et al was present in normal BM cells of the same patients in the remission period following relapse (Figure 2b ).
Discussion
With our vector and gene transfer protocol, we were able to detect the transgene until the end of follow-up, 5 years after ASCT. The existence of the transgene was confirmed with colony assays up to 6 months, after which they were no longer detected by this method. More sensitive nested-PCR method was still able to detect the transgene until the end of follow-up. Moreover, the number of marked cells was determined by Q-PCR and was found to be less than 1 in 10 5 cells at the end of the follow-up. The expression of the transgene was also followed by RT-PCR, but the sensitivity of the method did not allow the detection of any expression from such small number of positive cells at the end of the follow-up. Furthermore, we analyzed if the CD34 enriched cell population could include non-detectable contaminating transduced myeloma cells, later giving rise to relapse. We analyzed biopsy material from three relapsed patients using nested PCR and the results showed that the transgene was present only in normal cells and not in myeloma cells.
Our results suggest that the myeloma cells in relapse may not have been generated from the infused gene modified cells. This indicates that persistent cells surviving high-dose therapy are probably more important for relapse and progression than malignant cells contaminating the autologous graft, corroborating with recent results showing that the relapse rate following autologous transplantation with CD34 selected cells was independent of the presence of myeloma cells among infused cells (undetectable/o0.0002%/by a highly sensitive PCR-based method versus infusion of 0.0007-440 Â 10 6 myeloma cells) (Bourhis et al., unpublished). However, we cannot exclude the possibility that the myeloma cells in the harvest were not sufficiently transduced. In a similar study, a median transduction efficacy of 10% was obtained using the same vector to transduce stem cells Abbreviations: D, death; NA, not analyzed due to lack of sample; PCR, polymerase chain reaction.
Long-term follow-up of gene-marked CD34 þ cells E Alici et al from myeloma patients. The difference of efficacy can be explained with the different transduction protocols (number and duration of transductions as well as multiplicity of infection). 17 Our results corroborate with other previous, relatively shorter term, gene marking studies and furthermore help complete the overview about the nature of relapse in multiple myeloma. 20, 21 In this study, no side effects were seen due to gene marking including insertional mutagenesis. However, 2% transduction rate is associated with a low number of integrations per cell; hence, the risk of insertional mutagenesis is low.
Conclusion
Gene marking of the autologous cells in multiple myeloma HSC transplantation could provide valuable information about their contribution to relapse, as well as engraftment and disease progression. We have marked the HSCs of six myeloma patients receiving ASCT with a retroviral vector and were able to detect the transgene in normal BM cells for up to 5 years, at the end of follow-up. During this period, no marked myeloma cells were detected in relapse. Thus, it is unlikely that infused autologous cells significantly contributed to relapse. The gene marking was stable, well tolerated and no side effects were seen, nor did it appear to influence the course of the disease.
Patients, materials and methods
Patients
Each referred patient was considered individually based on the criteria in a previously published protocol with careful review of past medical history and present status. 22 Multiple myeloma patients that were intended to undergo high-dose chemotherapy and ASCT were eligible for the study, and the protocol was offered to the patients. The patient's decision to participate or decline RMGT did not alter the type or time point of ASCT. The study was approved by the ethics committee at Karolinska University Hospital, Huddinge in Stockholm. The first patient entering this study received transduced cells in December 1995.
Vector preparation
The G1Na retroviral vector. The replication deficient G1Na vector was constructed at Genetic Therapy Inc. 23 The bacterial neo r gene was inserted into a modified Moloney murine leukemia virus backbone. The vector had a number of modifications to minimize the risk of recombination between the vector and packaging construct, resulting in the event of creating replicationcompetent viruses.
The G1Na-producer cell line. The G1Na-producer cell line was created by transfection of the vector into the PA317 producer cell line. The vector containing supernatant obtained from the producer cell line was extensively tested for exogenous pathogens and replication-competent virus. The supernatant (provided by Genetic Therapy Inc.) to be used for human clinical studies had passed all quality controls. This vector supernatant had previously been used in another clinical trial. 15 Cell preparation. At the time of BM and blood cell collection, half of the cell harvest was left untreated, frozen and stored according to our current standard ) on genomic DNA from PB, BM and BB4 separated cells from BM at the time of relapse (a) and after relapse (b). The transgene was not detectable in PB both during and after relapse, whereas the BM was positive for the transgene at all times. Moreover, myeloma cells purified from the BM were negative for the transgene at relapse. Negative (normal genomic DNA), positive (vector plasmid DNA) and b-actin controls are also shown.
Long-term follow-up of gene-marked CD34
þ cells E Alici et al protocol. 22 The rest of the harvested blood or the marrow cells were CD34-sorted, and underwent RMGT.
CD34-sorting. CD34-sorting was preceded by cell centrifugation and concentration of the buffy-coat fraction of the cells followed by two times washing in phosphate-buffered saline (PBS) and incubation with anti-CD34 immunoglobulin M antibodies. Antibodybound cells were sorted using the CellPro Ceprate SC avidin-biotin column.
Gene transfer. The cells were exposed to the G1Na vector at a ratio of 5:1 vector particles per cell. The cells were incubated in vector-containing supernatant at 371C in the presence of stem cell factor (100 ng/ml), interleukin-3 (20 ng/ml), interleukin-6 (100 ng/ml), basic fibroblast growth factor (20 ng/ml) and protamine sulfate (4 mg/ml). After 12-h incubation, the cells were washed twice in 1 Â PBS. The incubation in fresh vector-containing supernatant with growth factors and protamine sulfate was repeated twice, with 6-h incubation periods, as described previously. 24 The cells were then frozen in a manner identical to the untreated cells. A small portion of the vector treated cells were plated for colony assay in methylcellulose medium with and without 1 mg/ml G418 at a concentration of 2 Â 10 3 cells/dish. After 10-14 days of culture, colonies were counted to provide the number of hematopoietic progenitors as well as the transduction rate of the cells infused. Individual colonies were picked and analyzed for the presence of the marker gene using PCR. Viable cell counts and flow cytometry analysis of CD34 þ cells were obtained before and after CD34-sorting, after vector treatment and finally before transplantation.
Polymerase chain reaction Genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). PCR amplification was performed in 50 ml volume containing 10 pmol of Neo1 (5 0 -CAA GAT GGA TTG CAC GCA GG-3 0 ) and Neo5 (5 0 -CCC GCT CAG AAG AAC TCG TC-3 0 ) primers for the neo r gene (Amersham Pharmacia Biotech, Uppsala, Sweden) and Bact1 (5'-CAT TGT GAT GGA CTC CGG AGA CGG) and Bact2 (5'-CAT CTC CTG CTC GAA GTC TAG AGC) primers for the b-actin gene (DNA technology, Aarhus, Denmark), 1X PCR buffer, 1.5 mM MgCl 2 , 0.3 mM dNTP mix and 1.25 U Taq polymerase from Gene Amp kit from Perkin-Elmer (Branchburg, New Jersey, USA). One microgrogram of genomic DNA from BM or PB sample was used. At every time point of receiving PB samples from the patients, DNA from PB samples of healthy donors extracted concurrently at the hospital Blood bank was used to prepare a negative DNA control for the PCR analysis. Twenty nanograms of the viral plasmid DNA was used as the positive control for the neo r PCR. The samples were incubated at 951C 5 min for 1 cycle, 941C 45 S, 611C 45 S, 721C 1 min for 30 cycles and 721C for 15 min for first round primers. Genomic DNA from BB4 (CD138) separated myeloma cells obtained from relapsed patients were also analyzed with the same protocol.
Nested PCR. One-tenth of the PCR product was subjected to nested PCR. Five microliters were transferred to a new 50 ml of the same reaction buffer including this time primer Neo2R (5 0 -GAG CAA GGT GAG ATG ACA GG-3 0 ) and Neo2 (5 0 -TGT CAA GAC CGA CCT GTC CG-3 0 ). The samples were incubated initially for 5 min at 951C followed by, 10 cycles (941C 1 min, 621C 1 min, 721C 1 min) and 30 cycles (941C 1 min, 581C 1 min, 721C 1 min) and further extension at 721C for 10 min. The resulting amplification product in the first and second round of amplification was 791 and 181 bp, respectively.
Quantitative PCR. For Q-PCR, 10 ml of DNA were subjected to a duplex TaqMan PCR with primers and probes specific for neo r and human Epo Receptor (hepo). In the PCR run, DNAs from mixtures of HT1080 cells containing a single copy of a retroviral vector carrying the neo r gene (HT1080Mo3TIN) with wild-type HT1080 cells were used as positive controls. The following relative concentrations of HT1080Mo3TIN were used: 0.01, 0.05, 0.1, 0.5, 1, 10 and 100%. Four water samples (carried through DNA extraction) and DNA from wild-type HT1080 cells were used as negative controls. All samples were run in triplicates and 50 cycles were run.
Methylcellulose assay BM and PB stem cells were cultured in methylcellulose with Isocove's modified Dulbecco's medium (IMDM), fetal calf serum, 5637-CM, bovine serum albumin, L-glutamine, antibiotics, 2-mercaptoethanol, hydrocortisone and erythropoietin. The cell densities were and 5 Â 10 5 cells/dish. G418 was added at 1 mg/ml to half of the Petri dishes.
Myeloma cell separation
Owing to the relatively low ratio of myeloma cells to normal BM cells at the times of relapse and after relapse, the myeloma cells were enriched by magnetic separation before marker gene analysis. BM cells were separated on density gradient. The cells were then incubated with the mouse-monoclonal antibody BB4 (Serotec), after which the BB4-positive cells were separated with immunomagnetic beads, as described previously. 25 With this method, a nearly pure population of myeloma cells was obtained from the BM of the patients that was analyzed for the presence of the transgene in tumor cells in relapse.
